Haldol Decanoas (Haloperidol Decanoate)

Haloperidol decanoate is prescribed for several psychiatric indications where long‑term control of psychotic symptoms is required.

• Maintenance therapy for adult patients with schizophrenia to reduce relapse risk and improve adherence.
• Management of acute psychotic episodes when a rapid, sustained antipsychotic effect is desired.
• Adjunctive use in schizoaffective disorder as part of a comprehensive treatment plan.
• Long‑acting depot option for individuals who have difficulty adhering to daily oral antipsychotics.
• Prevention of symptom recurrence in chronic psychotic disorders such as bipolar disorder with psychotic features.
• Transition support when switching from oral haloperidol to a depot formulation, often combined with short‑term oral coverage.

Side effects of haloperidol decanoate reflect its dopamine D2 antagonism and can be grouped into common and serious categories.

Common

• Extrapyramidal symptoms such as tremor, rigidity, or akathisia
• Sedation or drowsiness
• Dry mouth and constipation
• Elevated prolactin levels leading to menstrual changes or galactorrhea

Serious

• Tardive dyskinesia, a potentially irreversible movement disorder
• Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability
• Cardiac arrhythmias, including QT interval prolongation

Before initiating haloperidol decanoate, clinicians should evaluate several safety considerations and patient‑specific factors.

• Assess for a history of cardiovascular disease, arrhythmias, or prolonged QT interval.
• Evaluate the risk of extrapyramidal symptoms, especially in patients with Parkinson’s disease or prior EPS.
• Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation.
• Consider pregnancy and lactation status; safety data are limited, and risks should be weighed.
• Review liver and renal function, as impairment may affect drug metabolism and clearance.
• Use caution in patients with diabetes or metabolic syndrome due to possible hyperglycemia.

Haloperidol decanoate can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with other strong dopamine antagonists, which may increase the risk of severe extrapyramidal symptoms.
• Co‑administration with medications that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise haloperidol levels; dose adjustment may be needed.
• CYP3A4 inducers (e.g., carbamazepine, rifampin) can reduce plasma concentrations, potentially diminishing efficacy.
• CNS depressants, including benzodiazepines or alcohol, may enhance sedation.
• Anticholinergic agents may mask early signs of extrapyramidal side effects.